TerminatedNot applicableNCT04567251

Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy

This study represents a survivorship protocol that focuses on cognition and health-related quality of life (HRQoL) in cancer patients that have received prior brain irradiation. The primary purpose of this study is to assess the feasibility of using a digital symptom tracking application focused on HRQoL and cognition in cancer survivors who received brain irradiation.

Checked against the public recordLast updated May 14, 2025 · Source: ClinicalTrials.gov

StatusTerminated
PhaseNot applicable
U.S. locations1
SponsorDuke University
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Duke University
Interventions being studied
Other: Noona® application
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: 1. Cancer survivors who received cranial irradiation including, but not limited to, primary brain tumor, brain metastases, lung cancer receiving prophylactic brain irradiation, long-term survivors of pediatric cancers 2. Initial radiation must have been completed more than 6 months prior to enrollment. Acceptable radiation therapies include fractionated partial brain irradiation, whole brain irradiation, or stereotactic radiosurgery (for any modality at least a total cumulative dose of 20 Gy) of at least 20 Gy 3. Age ≥ 18 years at the time of entry into the study 4. Karnofsky performance score (KPS) ≥ 70 or Eastern Cooperative Oncology Group (ECOG) grade ≤ 2 5. No imaging evidence of disease progression within 4 months of enrollment 6. Life expectancy \> 6 months per treating neuro-oncology providers 7. Access to a smartphone, tablet, or computer with capability to utilize the mobile symptom-tracking application 8. Subject must be fluent in English Exclusion Criteria: 1\. Active psychiatric illness

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Duke University Medical CenterDurham, North Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 14, 2025. Always confirm current availability with the study team.

View original record ↗